Roivant Sciences Ltd. financial data

Symbol
ROIV on Nasdaq
Industry
Pharmaceutical Preparations
Location
Clarendon House, 2 Church Street, Hamilton Hm11, Bermuda
State of incorporation
Bermuda
Fiscal year end
March 31
Latest financial report
10-Q - Q3 2024 - Nov 12, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.98K % +209%
Quick Ratio 8 %
Debt-to-equity 12.1 % -84.6%
Return On Equity 78.5 %
Return On Assets 70.6 %
Operating Margin 2.68K %

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 728M shares -9.45%
Common Stock, Shares, Outstanding 733M shares -8.43%
Entity Public Float 8B USD +1697%
Common Stock, Value, Issued 0 USD
Weighted Average Number of Shares Outstanding, Basic 735M shares -4.51%
Weighted Average Number of Shares Outstanding, Diluted 735M shares -4.51%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 159M USD +128%
Research and Development Expense 538M USD +8.2%
General and Administrative Expense 203M USD +129%
Operating Income (Loss) 4.27B USD -59.8%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 4.67B USD +7.05%
Income Tax Expense (Benefit) 42.3M USD +955%
Net Income (Loss) Attributable to Parent 4.81B USD +24.4%
Earnings Per Share, Basic 6.15 USD/shares +22.5%
Earnings Per Share, Diluted 5.82 USD/shares +22.5%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 1.96B USD +39.1%
Marketable Securities, Current 3.43B USD
Cash, Cash Equivalents, and Short-term Investments 5.39B USD
Inventory, Net 34M USD +705%
Other Assets, Current 94.2M USD -34.3%
Assets, Current 5.8B USD +274%
Property, Plant and Equipment, Net 13.7M USD -44.1%
Operating Lease, Right-of-Use Asset 43M USD -11.6%
Intangible Assets, Net (Excluding Goodwill) 136M USD -6.23%
Other Assets, Noncurrent 36.9M USD -25.9%
Assets 6.21B USD +200%
Accounts Payable, Current 25.1M USD -43.1%
Employee-related Liabilities, Current 38.8M USD +26.4%
Accrued Liabilities, Current 111M USD -27.1%
Liabilities, Current 556M USD +109%
Operating Lease, Liability, Noncurrent 43.2M USD -11.2%
Other Liabilities, Noncurrent 295K USD -94.3%
Liabilities 626M USD -15.4%
Accumulated Other Comprehensive Income (Loss), Net of Tax -18M USD -487%
Retained Earnings (Accumulated Deficit) 396M USD
Stockholders' Equity Attributable to Parent 5.15B USD +443%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest 5.58B USD +321%
Liabilities and Equity 6.21B USD +200%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -193M USD +22.8%
Net Cash Provided by (Used in) Financing Activities -661M USD -8935%
Net Cash Provided by (Used in) Investing Activities -965K USD -1019%
Common Stock, Shares Authorized 7B shares 0%
Common Stock, Shares, Issued 733M shares -8.43%
Common Stock, Par or Stated Value Per Share 0 USD/shares
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -857M USD -254%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 1.97B USD +38.4%
Deferred Tax Assets, Valuation Allowance 767M USD +13.7%
Deferred Tax Assets, Gross 785M USD +12.6%
Operating Lease, Liability 57.2M USD -12.3%
Payments to Acquire Property, Plant, and Equipment 965K USD +139%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent 4.8B USD +23.4%
Lessee, Operating Lease, Liability, to be Paid 75.4M USD -22.6%
Operating Lease, Liability, Current 9.52M USD -12.7%
Lessee, Operating Lease, Liability, to be Paid, Year Two 9.66M USD -15.5%
Lessee, Operating Lease, Liability, to be Paid, Year One 10.7M USD -21.3%
Operating Lease, Weighted Average Discount Rate, Percent 0.07 pure -12.7%
Lessee, Operating Lease, Liability, to be Paid, Year Three 8.85M USD -13.9%
Deferred Tax Assets, Operating Loss Carryforwards 519M USD +22.8%
Lessee, Operating Lease, Liability, to be Paid, Year Four 8.87M USD -6.55%
Additional Paid in Capital 4.78B USD -10.2%
Depreciation, Depletion and Amortization 4.88M USD -16.4%
Share-based Payment Arrangement, Expense 565M USD +565%
Interest Expense 39.3M USD +14.6%